Panbela Therapeutics, Inc. has filed a prospectus supplement on July 30, 2024, to update and supplement information related to the issuance of shares underlying previously issued warrants. The supplement, filed with the SEC, pertains to the potential issuance of up to 2,433,789 shares of common stock, which includes 2,306,516 shares issued to investors and 127,345 shares underlying warrants issued to an underwriter. The company's common stock is traded on the OTCQB under the symbol 'PBLA' and was last reported at $0.35 per share on July 29, 2024. Additionally, on July 24, 2024, Panbela Therapeutics and its subsidiary, Cancer Prevention Pharmaceuticals, Inc., entered into a Loan Agreement with USWM, LLC for a term loan of $1,500,000. The loan, evidenced by a Term Promissory Note, bears interest and premium, with a maturity...Show More

Panbela Therapeutics, Inc. has filed a prospectus supplement on July 30, 2024, to update and supplement information related to the issuance of shares underlying previously issued warrants. The supplement, filed with the SEC, pertains to the potential issuance of up to 2,433,789 shares of common stock, which includes 2,306,516 shares issued to investors and 127,345 shares underlying warrants issued to an underwriter. The company's common stock is traded on the OTCQB under the symbol 'PBLA' and was last reported at $0.35 per share on July 29, 2024. Additionally, on July 24, 2024, Panbela Therapeutics and its subsidiary, Cancer Prevention Pharmaceuticals, Inc., entered into a Loan Agreement with USWM, LLC for a term loan of $1,500,000. The loan, evidenced by a Term Promissory Note, bears interest and premium, with a maturity date linked to the occurrence of a Qualifying Financing or Transaction, or by December 31, 2024. The proceeds from the loan are designated for specific uses, including payment to a contract research organization and other working capital purposes. The Loan Agreement includes customary covenants and events of default, and the company has pledged to complete a Qualifying Financing by the end of 2024 and a Qualifying Transaction by July 24, 2025. To secure the loan, Panbela Therapeutics and its subsidiary have granted a first priority security interest in their rights in the Asset Purchase Agreement to the lender.